ITV news10 Apr 2020 12:15
A patient was interviewed and talked openly about being on a trial. I would have expected discretion from trial patients as well as physicians. Sounds like updates would be acceptable to me.
In a note, analysts at 'house' broker finnCap introduced a 120p target price on the firm, saying the company's risk/reward profile was "skewed significantly to the upside" and that a successful outcome from the pilot phase of SNG001 will have "substantial commercial value".
Cheers